Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2608)	4/13/2010 9:47:49 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

KERX wants to continue its recent UT.<g> The stock closed most of its Apr5 UG, but not yesterday's.<g> bigcharts.marketwatch.com It announced today that several posters on Zerenex, its iron-based phosphate binder for the treatment of hyperphosphatemia in patients with end-stage renal disease who are on dialysis, have been accepted for presentation at the National Kidney Foundation 2010 Spring Clinical Meeting taking place April 13-17, 2010, in Orlando, FL These posters will be presented tomorrow: LONG-TERM USE OF FERRIC CITRATE IN ESRD PATIENTS THE SAFETY AND TOLERABILITY OF HIGHER DOSES OF FERRIC CITRATE IN CONTROLLING SERUM PHOSPHORUS IN ESRD PATIENTS IRON ABSORPTION WITH HIGHER DOSES OF FERRIC CITRATE IN CONTROLLING SERUM PHOSPHORUS IN ESRD PATIENTS The ACTAY is $5.75 and it seems the stock will be able to close its March 14,2008 DG <g> The stock is starting to get off from its longer term DT coming from the March 2006 H at $19.35 bigcharts.marketwatch.com Bernard